Modi Ventures

The firm's website names only Sahir Ali as its founder and public-facing principal. No additional investment committee members or partners are listed. Given the early-stage nature of the firm, Ali likely drives positioning and capital allocation, but the absence of a disclosed team limits the ability to confirm decision-making structure.

Modi Ventures operates a hybrid model. It makes direct seed-stage investments in early-stage companies — 44 as reported on its website — and it also commits capital to external venture funds, with 30 fund positions disclosed. The firm does not publish the proportion of capital allocated to each lane.

The firm targets early-stage investments, specifically seed stage, across both its direct startup portfolio and its fund commitments. The website lists no growth-stage or late-stage positions. The portfolio companies, such as Glyphic Biotechnologies and Kamau Therapeutics, are clinical-stage or earlier.

Modi Ventures concentrates on the intersection of technology and biology. Its website names AI applied to drug discovery, microfluidics hardware, multiomics, precision medicine, synthetic biology, gene editing, and living therapies as explicit focus areas. The firm does not invest in generalist health-tech or traditional biotech outside of AI-enabled platforms.

The deal-sourcing model is not publicly detailed. However, the fund-of-funds activity — 30 fund commitments alongside 44 direct investments — suggests that LP relationships with other bio-focused venture funds may surface proprietary early-stage deal flow. The firm's concentrated bioeconomy thesis likely draws inbound from AI-native biology founders.

Modi Ventures describes itself as an early-stage venture capital firm, not a family office. No single-family wealth origin is disclosed. The firm does not publicly report regulatory filings or an institutional limited-partner base, so its capital source remains opaque.

Disclosed direct portfolio companies include Generate Biomedicines, which builds generative AI models for protein-based therapeutics; Glyphic Biotechnologies, developing next-generation protein sequencing; Harbinger Health, focused on AI-enabled cancer screening; Kamau Therapeutics, a gene-correction company; and Brainomix, an AI-powered medical imaging platform. Fund-level holdings are not publicly named.